News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,447 Results
Type
Article (8044)
Company Profile (140)
Press Release (476358)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166768)
Career Advice (305)
Deals (25741)
Drug Delivery (7)
Drug Development (52881)
Employer Resources (14)
FDA (9761)
Job Trends (8576)
News (238252)
Policy (17922)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33154)
ALS (104)
Alzheimer's disease (974)
Antibody-drug conjugate (ADC) (262)
Approvals (10368)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6959)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (507)
Cancer (3628)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (172)
Celiac Disease (1)
Cell therapy (476)
Cervical cancer (34)
Clinical research (47849)
Collaboration (1239)
Commercialization (3)
Compensation (1449)
Complete response letters (34)
COVID-19 (755)
CRISPR (63)
C-suite (737)
Cystic fibrosis (85)
Data (5625)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4179)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73675)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87581)
Executive appointments (697)
FDA (12367)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (910)
Gene editing (125)
Generative AI (9)
Gene therapy (315)
GLP-1 (290)
Government (941)
Grass and pollen (2)
Guidances (281)
Healthcare (9314)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (156)
Infectious disease (943)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (59)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (505)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (528)
Marketing (8)
MASH (118)
Medical device (8650)
Medtech (8790)
Mergers & acquisitions (14378)
Metabolic disorders (704)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1818)
NextGen: Class of 2026 (3153)
Non-profit (841)
Obesity (223)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (472)
Patient recruitment (502)
Peanut (31)
People (41211)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15461)
Phase 2 (21372)
Phase 3 (14393)
Pipeline (7235)
Policy (18)
Postmarket research (1570)
Preclinical (6538)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3019)
Recruiting (6)
Regulatory (14791)
Reports (20)
Research institute (581)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (121)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2022)
Stomach cancer (3)
Supply chain (50)
Vaccines (318)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (111)
Last 7 days (459)
Last 30 days (1669)
Last 365 days (19133)
2026 (12075)
2025 (19251)
2024 (22988)
2023 (26539)
2022 (34587)
2021 (37178)
2020 (33480)
2019 (23257)
2018 (17496)
2017 (18765)
2016 (17918)
2015 (24269)
2014 (21679)
2013 (18138)
2012 (20221)
2011 (20440)
2010 (20333)
Location
Africa (228)
Alabama (73)
Alaska (2)
Arizona (300)
Arkansas (11)
Asia (17880)
Australia (2097)
California (11905)
Canada (3127)
China (517)
Colorado (481)
Connecticut (407)
Delaware (207)
Europe (24617)
Florida (1780)
Georgia (375)
Hawaii (3)
Idaho (46)
Illinois (695)
India (48)
Indiana (314)
Iowa (14)
Japan (398)
Kansas (101)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1193)
Massachusetts (7825)
Michigan (307)
Minnesota (559)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2610)
New Mexico (12)
New York (2811)
North Carolina (1267)
North Dakota (4)
Northern California (5961)
Ohio (276)
Oklahoma (14)
Oregon (16)
Pennsylvania (2244)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4942)
Tennessee (119)
Texas (1925)
United States (38673)
Utah (358)
Vermont (1)
Virginia (152)
Washington D.C. (38)
Washington State (921)
West Virginia (1)
Wisconsin (73)
484,447 Results for "metacrine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Metacrine and Equillium Mutually Agree to Terminate Definitive Merger Agreement
Metacrine, Inc. and Equillium, Inc. announced the mutual termination of their previously announced definitive merger agreement.
December 23, 2022
·
2 min read
Business
Metacrine Reports Third-Quarter 2022 Results
Metacrine, Inc., a clinical-stage biopharmaceutical company developing differentiated therapies for patients with gastrointestinal diseases, reported its third-quarter 2022 financial results.
November 14, 2022
·
7 min read
Deals
Equillium to Acquire Metacrine in All-Stock Transaction
Equillium, Inc. and Metacrine Inc., announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction.
September 6, 2022
·
13 min read
Deals
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
Equillium, Inc. and Metacrine, Inc. announced the mutual termination of their previously announced definitive merger agreement.
December 23, 2022
·
5 min read
Business
Metacrine Reports Second-Quarter 2022 Results
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its second-quarter 2022 financial results.
August 9, 2022
·
5 min read
Business
Metacrine Reports First-Quarter 2022 Results
Metacrine, Inc. reported its first-quarter 2022 financial results and provided a business update.
May 12, 2022
·
6 min read
Business
Metacrine Reports Fourth-Quarter 2021 Results
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its fourth-quarter 2021 financial results.
March 30, 2022
·
5 min read
Business
Metacrine Announces Executive Leadership Changes
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, announced that Ms. Trisha Millican has resigned her position as chief financial officer.
February 24, 2022
·
2 min read
Business
Metacrine Announces Resignation of Chief Medical Officer
Metacrine, Inc. today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to pursue a new opportunity.
December 27, 2021
·
2 min read
Business
Metacrine Reports Third-Quarter 2021 Results
Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, reported its third-quarter 2021 financial results.
November 11, 2021
·
6 min read
1 of 48,445
Next
